他汀类药物治疗家族性高胆固醇血症的疗效:一项长期队列研究。

Efficacy of statins in familial hypercholesterolaemia: a long term cohort study.

作者信息

Versmissen Jorie, Oosterveer Daniëlla M, Yazdanpanah Mojgan, Defesche Joep C, Basart Dick C G, Liem Anho H, Heeringa Jan, Witteman Jacqueline C, Lansberg Peter J, Kastelein John J P, Sijbrands Eric J G

机构信息

Department of Internal Medicine, Erasmus University Medical Centre, PO box 2040, 3000 CA Rotterdam, Netherlands.

出版信息

BMJ. 2008 Nov 11;337:a2423. doi: 10.1136/bmj.a2423.

Abstract

OBJECTIVE

To determine the efficacy of statin treatment on risk of coronary heart disease in patients with familial hypercholesterolaemia.

DESIGN

Cohort study with a mean follow-up of 8.5 years.

SETTING

27 outpatient lipid clinics.

SUBJECTS

2146 patients with familial hypercholesterolaemia without prevalent coronary heart disease before 1 January 1990.

MAIN OUTCOME MEASURES

Risk of coronary heart disease in treated and "untreated" (delay in starting statin treatment) patients compared with a Cox regression model in which statin use was a time dependent variable.

RESULTS

In January 1990, 413 (21%) of the patients had started statin treatment, and during follow-up another 1294 patients (66%) started after a mean delay of 4.3 years. Most patients received simvastatin (n=1167, 33 mg daily) or atorvastatin (n=211, 49 mg daily). We observed an overall risk reduction of 76% (hazard ratio 0.24 (95% confidence interval 0.18 to 0.30), P<0.001). In fact, the risk of myocardial infarction in these statin treated patients was not significantly greater than that in an age-matched sample from the general population (hazard ration 1.44 (0.80 to 2.60), P=0.23).

CONCLUSION

Lower statin doses than those currently advised reduced the risk of coronary heart disease to a greater extent than anticipated in patients with familial hypercholesterolaemia. With statin treatment, such patients no longer have a risk of myocardial infarction significantly different from that of the general population.

摘要

目的

确定他汀类药物治疗对家族性高胆固醇血症患者冠心病风险的疗效。

设计

平均随访8.5年的队列研究。

地点

27家门诊脂质诊所。

研究对象

1990年1月1日前无冠心病史的2146例家族性高胆固醇血症患者。

主要观察指标

将接受治疗和“未治疗”(延迟开始他汀类药物治疗)的患者的冠心病风险与他汀类药物使用作为时间依赖性变量的Cox回归模型进行比较。

结果

1990年1月,413例(21%)患者开始他汀类药物治疗,随访期间另有1294例患者(66%)平均延迟4.3年后开始治疗。大多数患者接受辛伐他汀(n = 1167,每日33毫克)或阿托伐他汀(n = 211,每日49毫克)治疗。我们观察到总体风险降低了76%(风险比0.24(95%置信区间0.18至0.30),P < 0.001)。事实上,这些接受他汀类药物治疗的患者发生心肌梗死的风险并不显著高于来自普通人群的年龄匹配样本(风险比1.44(0.80至2.60),P = 0.23)。

结论

与目前建议的剂量相比,较低剂量的他汀类药物在家族性高胆固醇血症患者中降低冠心病风险的程度比预期更大。使用他汀类药物治疗后,这类患者发生心肌梗死的风险与普通人群无显著差异。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c20/4787069/db79bcb096b1/verj594622.f1.jpg

相似文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索